Intraperitoneal -Interferon Alternating with Cisplatin in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study

By Berek J.S.   Markman M.   Blessing J.A.   Kucera P.R.   Nelson B.E.   Anderson B.   Hanjani P.  

Gynecologic Oncology, Vol. 74, Iss. 1, 1999-07 ,pp. : 48-52

Elsevier

Access to resources Recommend Favorite

A Phase II Study of Intraperitoneal Cisplatin and Thiotepa in Residual Ovarian Carcinoma: A Gynecologic Oncology Group Study

By Feun L.G.   Blessing J.A.   Major F.J.   DiSaia P.J.   Alvarez R.D.   Berek J.S.  

Gynecologic Oncology, Vol. 71, Iss. 3, 1998-12 ,pp. : 410-415

Elsevier

Access to resources Recommend Favorite

A Phase II Trial of CI-958 in Recurrent Platinum-Sensitive Ovarian Carcinoma: A Gynecologic Oncology Group Study

By Hoffman M.A.   Blessing J.A.   Nunez E.R.  

Gynecologic Oncology, Vol. 81, Iss. 3, 2001-06 ,pp. : 433-435

Elsevier

Access to resources Recommend Favorite

Phase II Trial of CI-958 in Recurrent Platinum-Refractory Ovarian Carcinoma - A Gynecologic Oncology Group Study

By Hoffman M.A.   Blessing J.A.   Morgan M.  

Gynecologic Oncology, Vol. 79, Iss. 3, 2000-12 ,pp. : 463-465

Elsevier

Access to resources Recommend Favorite

A Phase I Study of Intraperitoneal Interferon-α_2b and Intravenous cis-Platinum plus Cyclophosphamide Chemotherapy in Patients with Untreated Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Pilot Study

By Moore D.H.   Valea F.   Walton L.A.   Soper J.   Clarke-Pearson D.   Fowler Jr. W.C.  

Gynecologic Oncology, Vol. 59, Iss. 2, 1995-11 ,pp. : 267-272

Academic Press

Access to resources Recommend Favorite